Back to today’s briefing

Story perspectives

Eli Lilly Cuts Zepbound Price for Uninsured Patients

2/25/2025

23 2

Summary

Eli Lilly Reduces Prices

Eli Lilly is slashing the price of its weight-loss drug Zepbound, now available in higher doses for $499 per month on its LillyDirect website—nearly 23% cheaper than the auto-injector version. This strategic decision seeks to improve access for uninsured patients, responding to the growing competition in the weight-loss industry.

Summary

Eli Lilly Prepares Launch

Eli Lilly is gearing up for a successful 2026 launch of its oral GLP-1 drug, orforglipron, by stockpiling an impressive $548.1 million worth. This proactive move aims to prevent the supply shortages that plagued its previous drugs, Mounjaro and Zepbound. With late-stage trials showing encouraging results for obesity and diabetes, the anticipation is building.

1 of 2

Eli Lilly Reduces Prices

Eli Lilly is slashing the price of its weight-loss drug Zepbound, now available in higher doses for $499 per month on its LillyDirect website—nearly 23% cheaper than the auto-injector version. This strategic decision seeks to improve access for uninsured patients, responding to the growing competition in the weight-loss industry.

1 / 2